Canada Semen Analysis Market Forecast 2025-2032

The Canada semen analysis market is anticipated to grow with a CAGR of 6.56% over the forecast period 2025-2032. The market was valued at $78.20 million in 2024 and is expected to reach a revenue of $130.33 million by 2032.

The Canadian semen analysis market’s growth is attributed to increasing incidences of male infertility, advancements in diagnostic technologies, the expansion of fertility clinics and ART centers, and growing awareness of reproductive health.

The rising preference for convenient and private home semen analysis kits also contributes to market expansion. However, the Canadian semen analysis market is likely to be hindered by the high costs of advanced diagnostic procedures, sociocultural stigmas associated with male infertility, and fertility testing.

MARKET INSIGHTS

Infertility, defined as the failure to conceive after one year of regular unprotected intercourse, affects 15% of couples in Canada. Male factors are identified as the sole cause in 30% of cases, while female factors account for 35%, and 20% of cases result from a combination of both.

Canada’s total fertility rate (TFR) reached a record low of 1.33 children per woman in 2022, marking the lowest level since records began. Additionally, 10 out of 13 provinces and territories reported a record-low TFR in 2022. The decrease from 2021 to 2022 (-7.4%) represents the most significant drop since the early 1970s, during the “baby bust” era.

The market’s growth is propelled by advancements in diagnostic technologies, particularly the integration of artificial intelligence (AI) and machine learning (ML), which enable precise assessments of sperm count, motility, and morphology.

Moreover, the expansion of fertility clinics and ART centers, coupled with the growing awareness of fertility testing and reproductive health, ensures broader access to reliable diagnostic solutions. Despite challenges, Canada’s market continues to evolve, driven by increased public awareness and the growing demand for male fertility testing solutions.

SEGMENTATION ANALYSIS

The Canada semen analysis market is segmented into diagnostic technique, testing kits and reagents, age group, and end-user. The diagnostic technique category is further classified into microscopic examination, computer-assisted semen analysis (CASA), and other diagnostic techniques.

CASA systems, combining advanced imaging and computational tools, are increasingly being adopted in fertility clinics and diagnostic laboratories for their superior accuracy and efficiency. Testing kits, particularly home-based options, are also gaining traction, addressing sociocultural barriers while promoting early and private diagnoses.

With the lowest TFR recorded in Canadian history and infertility rates affecting a significant portion of the population, the demand for semen analysis and related diagnostic services is projected to rise. While addressing cost barriers and overcoming societal stigmas remain critical, the integration of AI-driven technologies and the expansion of fertility-focused infrastructure are expected to drive substantial growth in Canada’s semen analysis market.

COMPETITIVE INSIGHTS

Some of the top players in the Canada semen analysis market include bioMérieux SA, Cooper Companies Inc, DNA Diagnostics Center, Hamilton Thorne Inc, etc.

Medical Electronic Systems (MES) specializes in the design, manufacture, and marketing of automated semen analysis instruments and supporting software for fertility and infertility testing. Their product line includes FDA and CE-cleared Sperm Quality Analyzers (SQA), laboratory accessories, and at-home testing kits.

It serves reproductive centers, hospitals, reference laboratories, doctor’s offices, and individuals at home. Founded in 1992, MES operates globally with offices in the USA, Belgium, Israel, India, and China and maintains an extensive network of international distributors. The company is ISO 13485 certified as a medical device manufacturer.